Statin Administration and the Risk of New-Onset Diabetes (pp. 113-120)
Authors: Jan Fedacko, RB Singh, Daniel Pella, Dominik Pella, and Anna Gvozdjakova
Abstract: There is evidence that long-term use of statins can predispose to new-onset incident diabetes. A recent meta-analysis demonstrated that statin therapy was associated with a risk of incident diabetes. The study showed that relative reduction in low-density lipoprotein cholesterol (LDL-C) was a good indicator of the risk of new-onset diabetes. The overall risk of incident diabetes increased by 11% and the group with intensive LDL-C reduction statin had an 18% increase in the likelihood of developing diabetes. The risks of incident diabetes were 13% and 29% in the subgroups with 30–40% and 40–50% reductions in LDL-C, respectively. These findings showed that LDL-C decrease may provide a dynamic risk assessment parameter for new-onset diabetes. LDL-C lowering may be positively related to the risk of new-onset diabetes. It is important to perform blood glucose monitoring if there is a 30% decline in LDL cholesterol during lipid lowering therapy, to detect incident diabetes in these populations. However, all statins do not have the same effects: rosuvastatin and atorvastatin administration is more commonly and pitavastatin least commonly associated with diabetes. More studies are required to examine whether intensive therapy with statin can cause new-onset diabetes, which may be due to decreased insulin sensitivity.